Route One Investment Company LP Lifted Fastenal Company (FAST) Holding; 5 Analysts Are Bullish Momenta Pharmaceuticals, Inc. (MNTA) Last Week

April 21, 2018 - By Linda Rogers

Fastenal Company (NASDAQ:FAST) Logo

Among 12 analysts covering Momenta Pharmaceuticals (NASDAQ:MNTA), 5 have Buy rating, 2 Sell and 5 Hold. Therefore 42% are positive. Momenta Pharmaceuticals had 29 analyst reports since August 6, 2015 according to SRatingsIntel. On Tuesday, October 11 the stock rating was upgraded by Barclays Capital to “Overweight”. The rating was initiated by JP Morgan on Friday, November 13 with “Overweight”. The rating was maintained by Stifel Nicolaus with “Buy” on Wednesday, August 2. Maxim Group upgraded the stock to “Hold” rating in Friday, January 8 report. The firm earned “Hold” rating on Tuesday, October 31 by Cowen & Co. The stock of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) earned “Sell” rating by Maxim Group on Wednesday, September 7. Stifel Nicolaus downgraded Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) on Thursday, October 5 to “Hold” rating. Leerink Swann downgraded the shares of MNTA in report on Wednesday, February 22 to “Mkt Perform” rating. The firm earned “Equal-Weight” rating on Monday, May 22 by Barclays Capital. Aegis Capital initiated Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) on Tuesday, November 22 with “Hold” rating. See Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) latest ratings:

22/02/2018 Broker: Stifel Nicolaus Old Rating: Hold New Rating: Buy Upgrade
30/01/2018 Broker: Stifel Nicolaus Rating: Hold New Target: $18.0 Maintain
31/10/2017 Broker: Cowen & Co Rating: Hold New Target: $15.0 Maintain

Route One Investment Company Lp increased Fastenal Company (FAST) stake by 4.39% reported in 2017Q4 SEC filing. Route One Investment Company Lp acquired 182,000 shares as Fastenal Company (FAST)’s stock declined 2.22%. The Route One Investment Company Lp holds 4.33M shares with $236.70M value, up from 4.15 million last quarter. Fastenal Company now has $14.53 billion valuation. The stock decreased 0.18% or $0.09 during the last trading session, reaching $50.49. About 2.49M shares traded. Fastenal Company (NASDAQ:FAST) has risen 5.62% since April 21, 2017 and is uptrending. It has underperformed by 5.93% the S&P500.

Investors sentiment decreased to 1.05 in 2017 Q4. Its down 0.25, from 1.3 in 2017Q3. It turned negative, as 37 investors sold FAST shares while 215 reduced holdings. 91 funds opened positions while 174 raised stakes. 232.28 million shares or 0.94% less from 234.48 million shares in 2017Q3 were reported. Ent Fin Corporation invested in 0% or 116 shares. 35,795 are owned by Stonebridge Cap Mgmt. Boyd Watterson Asset Mngmt Limited Liability Oh holds 19,895 shares. Andra Ap has 39,100 shares for 0.05% of their portfolio. Douglass Winthrop Advsr Limited stated it has 1.89% in Fastenal Company (NASDAQ:FAST). The New York-based Cornerstone Capital Mgmt Holdg Ltd Limited Liability Company has invested 0.02% in Fastenal Company (NASDAQ:FAST). Cibc Asset invested 0.01% in Fastenal Company (NASDAQ:FAST). Bell Comml Bank holds 0.15% of its portfolio in Fastenal Company (NASDAQ:FAST) for 10,065 shares. Marshfield Associate holds 1.54 million shares. Moreover, Old Second National Bank Of Aurora has 0.01% invested in Fastenal Company (NASDAQ:FAST) for 300 shares. Department Mb Bankshares N A holds 0.02% or 2,855 shares in its portfolio. Geode Cap Management Limited Liability Com accumulated 3.49M shares. Mutual Of America Capital Mgmt Ltd Llc has 0.03% invested in Fastenal Company (NASDAQ:FAST) for 37,899 shares. Whittier Trust Of Nevada holds 1,368 shares or 0.01% of its portfolio. State Bank Of America De owns 1.72M shares for 0.02% of their portfolio.

Among 19 analysts covering Fastenal (NASDAQ:FAST), 10 have Buy rating, 1 Sell and 8 Hold. Therefore 53% are positive. Fastenal had 77 analyst reports since July 21, 2015 according to SRatingsIntel. BMO Capital Markets maintained the shares of FAST in report on Tuesday, June 6 with “Hold” rating. Credit Suisse initiated Fastenal Company (NASDAQ:FAST) on Tuesday, September 15 with “Neutral” rating. The firm earned “Buy” rating on Wednesday, December 6 by Raymond James. Stifel Nicolaus maintained Fastenal Company (NASDAQ:FAST) on Monday, August 21 with “Hold” rating. Longbow upgraded the stock to “Buy” rating in Friday, June 2 report. The rating was maintained by Stifel Nicolaus with “Hold” on Wednesday, January 17. The rating was maintained by BMO Capital Markets with “Hold” on Monday, August 21. The firm has “Buy” rating given on Wednesday, April 11 by Stephens. On Wednesday, July 12 the stock rating was upgraded by Robert W. Baird to “Outperform”. Stephens initiated it with “Buy” rating and $5400 target in Friday, June 2 report.

Since December 15, 2017, it had 0 insider buys, and 4 selling transactions for $2.06 million activity. 7,500 Fastenal Company (NASDAQ:FAST) shares with value of $424,808 were sold by Drazkowski William Joseph. Polipnick Gary A. had sold 2,634 shares worth $140,793. The insider Miller Charles S. sold 26,250 shares worth $1.48 million. 242 shares were sold by Jansen James C, worth $14,036.

Since December 13, 2017, it had 0 insider purchases, and 12 insider sales for $2.01 million activity. $823,346 worth of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) was sold by WHEELER CRAIG A on Tuesday, April 10. Stoner Elizabeth sold $154,280 worth of stock. Shares for $75,942 were sold by Kaundinya Ganesh Venkataraman on Monday, February 12. Leicher Bruce sold $75,333 worth of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) on Monday, February 12. Storer Scott M had sold 3,972 shares worth $60,216 on Monday, February 12.

Momenta Pharmaceuticals, Inc., a biotechnology company, focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for autoimmune diseases in the United States. The company has market cap of $1.56 billion. The companyÂ’s complex generics programs include Enoxaparin sodium injection, a generic version of Lovenox that is indicated for the prevention and treatment of deep vein thrombosis, as well as supports the treatment of acute coronary syndromes; GLATOPA, a generic version of once-daily COPAXONE for the treatment of patients with relapsing-remitting multiple sclerosis; and GLATOPA, a generic product candidate for three-times-weekly COPAXONE. It currently has negative earnings. The Company’s biosimilars programs comprise M923, a biosimilar of HUMIRA for the treatment of patients with rheumatoid arthritis, crohn's disease, ulcerative colitis, and psoriasis; and M834, a biosimilar of ORENCIA for the treatment of rheumatoid arthritis and juvenile idiopathic arthritis, as well as other biosimilar candidates.

Fastenal Company (NASDAQ:FAST) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: